Meadville, PA – Meadville Medical Center (MMC), in collaboration
with Wesbury Retirement Community (Wesbury), today announced a joint effort
to manage the surge of COVID-19 patients in Crawford County.
“The two organizations are providing mutual aid in order to maximize
the overall capacity and efficiency of healthcare services in Crawford
County in the battle against COVID-19,” said Philip Pandolph, Chief
Executive Officer at MMC.
Under the guidance of Dr. David Williams, who is lead attending physician
of Wesbury’s COVID-19 unit, a multidisciplinary team from MMC is
available for supplemental support to residents who are positive with
COVID-19. The team, consisting of MMC Pulmonologist, Dr. Andra Fee, respiratory
therapists, nurse practitioners, and infectious disease specialists, complete
routine rounding of residents and is available, as needed.
“The challenge that COVID-19 puts on care facilities can be extensive.
The dedication and commitment of our staff has quickly become apparent,”
said Brian Nageotte, President and CEO at Wesbury. He continued, “The
ability to provide such a high level of medical attention onsite will
benefit not only the residents but staff and community as well.”
Residents who return to Wesbury from being an inpatient at MMC, along with
any post-acute care patients who transfer to Wesbury, are all placed into
a unit specifically designed to treat and manage individuals with COVID-19.
“Cohorting residents who have COVID-19 is a very important step for
both treatment and limiting spread of the virus. Combining this with excellent
medical attention, negative air pressure rooms for isolation, a highly
trained staff and thoughtfully designed procedures we are confident that
our residents are safe,” said Sheila Bundy, Director of Healthcare
Services at Wesbury.
Both MMC and Wesbury have initiated monoclonal antibody infusions for treatment
of individuals most at risk to develop serious illness associated with
COVID-19. Monoclonal antibodies assist the immune system with fighting
off viruses, and on November 9, 2020, the U.S. Food and Drug Agency approved
use of the monoclonal antibody Bamlanivimab for treatment of COVID-19
in adult and pediatric patients.